CNS Pharmaceuticals Announces Closing Of Initial Public Offering of Common Stock

Houston, TX – November 13, 2019 – CNS Pharmaceuticals, Inc. (NASDAQ: CNSP) (“Company”), a pre-clinical stage biotechnology company specializing in the development of novel treatments for brain tumors, today announced the closing of its initial public offering of 2,125,000 shares of common stock at an initial public offering price of $4.00 per share. The gross […]

The Smartest Ways to Invest in CBD Growth Right Now

Palm Beach, FL – November 13, 2019 — CBD is quickly becoming a multi-billion-dollar business.  In fact, sales of products containing CBD are expected to grow 700% in 2019 year over year, says the Brightfield Group.  “The CBD market has been growing rapidly, but we will see unprecedented growth in 2019,” Brightfield Managing Director, Bethany […]

Today’s New Way To Fight Cancer Focusing On Metabolic Therapies

Palm Beach, FL –November 13, 2019 – For decades researchers have been trying to find newer and more effective ways to fight cancer cells. Today much research is focused on attacking the cancerous cells growth. The reasoning is that denying these cells energy, they will die. The idea is that by using targeted therapies only […]

WebSafety Inc., building disrupting APP to solve the Distracted Driving Crisis

WEBSAFETY is leveraging current market share in parental monitoring marketplace to introduce a new app with immediate highway safety for drivers while providing analytics for this new untapped marketplace.   Las Vegas, NV – November 13, 2019 – WEBSAFETY Inc. (OTCPK: WBSI), with more than 170,000 followers in social media and a parental monitor app […]

Moleculin Announces Beginning of Preclinical Development of New Approach to Pancreatic Cancer

Inhibitor of glycolysis provides opportunity to attack the metabolism of tumors   Houston, TX – November 13, 2019 – Moleculin Biotech, Inc., (Nasdaq: MBRX) (“Moleculin” or the “Company”), a clinical stage pharmaceutical company with a broad portfolio of drug candidates targeting highly resistant tumors, announced it has begun preclinical testing of its drug candidate, WP1122, […]